FDA May Step In After High Court Shields Generic-Drug Cos.

Law360, New York (June 24, 2013, 6:59 PM EDT) -- All eyes are on the U.S. Food and Drug Administration after the U.S. Supreme Court on Monday blocked design defect lawsuits against generic-drug makers, according to experts who predict that regulators could take action forcing generics companies to shoulder more responsibility for their warning labels.

Within hours of Monday's decision in Mutual Pharmaceutical Co. Inc. v. Bartlett, there were clear signs of the tremendous pressure facing the FDA. Consumer rights group Public Citizen, which filed an amicus brief in the case on behalf of Democratic lawmakers,...
To view the full article, register now.